A5057907024- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- Chemical Reactions and Isotopes
- Neutropenia and Cancer Infections
- Blood disorders and treatments
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- Blood groups and transfusion
- Prostate Cancer Treatment and Research
Antalya Eğitim ve Araştırma Hastanesi
2024-2025
Antalya IVF
2021
Abstract Background Neoadjuvant treatment is the standard in locally advanced ESCC. However, optimal chemotherapy regimen not known. Method This a retrospective observational cohort study conducted with propensity score matching. Patients resectable ESCC from 13 tertiary centers Türkiye were screened between January 2011 and December 2021. We compared efficacy safety of neoadjuvant chemoradiotherapy CF CROSS regimens patients Results Three hundred sixty‐two screened. who received induction (...
The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. aim study was to evaluate prognostic status early triple negative breast cancer(TNBC). In TNBC patients who were treated with chemotherapy (NAC) and surgery analyzed retrospectively. primary analyze status(Her2-0 Her2-low) on pathological complete response (pCR). secondary objectives disease free survival (DFS) overall (OS). 620 female cancer evaluated. 427 (68.9%) had Her2-0 193(31.1%) her2-low...